VNA-318 CNS mitophagy inducer program
phase 1drug program · high · Wed Dec 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve cognition and provide longer-term disease-modifying effects in CNS age-related or chronic disease by restoring mitochondrial function and reducing inflammation.
Orally bioavailable, brain-penetrant small molecule with dual mode of action; described as a mitophagy inducer against a novel target.
First subjects dosed in first-in-human Phase 1 clinical trial; Series A funding closed to fund the Phase 1 trial and plan efficacy-focused Phase 1b/2a trials.
Robust preclinical dataset reportedly showed neuroprotective effects and potential to improve cognition; no human efficacy results provided.